Arno Therapeutics to Present Promising Data From Phase I

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Arno Therapeutics to Present Promising Data From Phase I Trial of Onapristone at AACR Annual Meeting 2015

FLEMINGTON, N.J., April 21, 2015 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced data from three posters supporting the ongoing clinical development program for lead compound onapristone at the American Association for Cancer Research (AACR) Annual Meeting 2015 , being held April 18-22 in Philadelphia, Pa.

Alex Zukiwski, MD, Chief Executive Officer of Arno Therapeutics, commented, "The AACR Annual Meeting offers members of the oncology community an important opportunity to highlight new cancer research and discoveries that advance the field toward improved therapeutic options for patients. This year, we are pleased to present data from our preclinical and clinical studies that support the continued development of our lead oncology drug candidate onapristone – particularly the data from our Phase I study demonstrating that onapristone exhibits a well-tolerated safety profile at the highest evaluated extended-release dose level – and the continued development of a companion diagnostic for onapristone that identifies activated progesterone receptor (APR) tumor status as a predictor of anti-progestin activity."

Data results from the three studies being presented are as follows:

Abstract #4512 (Poster #10) – Onapristone in patients (pts) with progesterone receptor (PR)-expressing cancers: PK results from part 1 of a randomized, parallel-dose phase 1 study

• Poster Session: PO.ET05.01. Pharmacokinetics and Pharmacodynamics
• Date, Location: Tuesday, April 21; 1:00-5:00 p.m. ET

Validated pharmacokinetic (PK) data from 35 of 52 enrolled patients in stage 1 of the multi-center, open-label, randomized, parallel-group Phase 1 study (NCT02052128) evaluating onapristone in women with progesterone receptor (PR) expressing tumors demonstrate a longer onapristone half-life (T 1/2 ) which supports using an extended-release formulation of the compound. Arno has developed the extended release formulation to mitigate high concentration spikes that may have contributed to the previously described adverse events of liver function test (LFT) elevations observed in patients receiving an immediate-release formulation in prior clinical trials. The study showed that drug release rate (AUC) and drug concentration (C max ) are dose proportional and allow dosing flexibility. In addition, the study showed prolonged exposure-minimizing concentration spikes is best achieved with a twice-daily, extended-release formulation. There were no clinically significant LFT elevations in the absence of liver metastases in 30 patients exposed to the extended-release formulation.

The recommended Phase 2 dose (RP2D) was established at the highest extended-release dose level – 50 mg twice daily (BID) – based on safety and PK data, and is being further explored in the expansion phase of the study. The Phase II component of the modified Phase I/II clinical study is evaluating onapristone in women with recurrent or metastatic endometrioid tumors that have been shown to express the activated progesterone receptor (APR).

Abstract #4523 (Poster #21) – Population pharmacokinetic (PPK) modeling of onapristone in patients (pts) with progesterone receptor (PR)-expressing cancers

• Poster Session: PO.ET05.01. Pharmacokinetics and Pharmacodynamics
• Date, Location: Tuesday, April 21; 1:00-5:00 p.m. ET

Validated pharmacokinetic (PK) data from 42 patients were analyzed from the completed Stage 1 portion of the multi-center, open-label, randomized, parallel-group Phase 1 study (NCT02052128) evaluating onapristone in women with progesterone receptor (PR) expressing tumors. During the study, blood samples from patients receiving extended-release or immediate-release formulations of onapristone were taken at regular intervals and the onapristone plasma concentrations were measured.

The study showed that a two-compartment open population pharmacokinetic (PPK) model adequately described the total plasma onapristone time-concentration curve with linear elimination. A central volume equivalent to the circulating blood volume and a large volume of the deep compartment suggest a substantial tissue diffusion. No detectable PK/safety signal was detected and, as anticipated, concentration fluctuations were less with the extended release versus immediate release formulation.

Abstract #3471 (Poster #24) – Comparative assessment of in vitro activity and activated progesterone receptor (APR) biomarker predictivity for multiple antiprogestins

• Poster Session: PO.EN02.01. Hormonal Regulation of Tumor Growth and Metastasis
• Date, Location: Tuesday, April 21; 8:00 a.m. - 12:00 p.m. ET

The study examined the correlation of activated progesterone receptor (APR) – which is predictive of onapristone anti-proliferative effects – to the anti-proliferative effects of several different anti-progestins, including Type I & Type II, and steroidal/non-steroidal chemical structures (growth supplements), in two progesterone receptor (PR) expressing breast cancer cell lines, T47D and CAMA-1.

The study found that the cell line T47D expresses APR and is sensitive to direct anti-progestin effect in steroidal growth supplement (FBS) and to estradiol and progesterone growth stimulation in non-steroidal growth supplement (SFFBS). In the T47D cell line, there was an antagonism by all anti-progestins, and APR positive status was reversed at 30 hours completely in 3 of 6 cases and incompletely in 3 of 6 cases. The study showed that the CAMA-1 cell line does not express APR, is weakly stimulated by estradiol and progesterone, and anti-progestins have inconsistent effects in this cell line. The study concluded that APR status is a predictor of anti-progestin action.

Arno is currently enrolling patients in a Phase II clinical trial of onapristone in patients with metastatic or recurrent endometrioid tumors that express the activated progesterone receptor (APR), and in a separate Phase I/II clinical trial of onapristone in patients with castration resistant prostate cancer whose tumors are progesterone receptor (PR) positive.

Onapristone is an oral, anti-progestin hormone blocker that has been shown in previous Phase II clinical trials (not sponsored by Arno) to exhibit anti-tumor activity in patients with breast cancer. In pre-clinical testing, onapristone has been shown to block the activation of PR, which is believed to be a mechanism that inhibits the growth of APR driven breast, endometrial and other, primarily gynecological, tumors. APR has the potential to function as a biomarker of anti-progestin activity, as detected by a companion diagnostic currently under development with Arno's partner, Leica Biosystems.

About Arno Therapeutics

Arno Therapeutics is a clinical stage biopharmaceutical company developing innovative products for the treatment of cancer and other life threatening diseases. Arno has exclusive worldwide rights to develop and market three innovative product candidates. These compounds are in clinical or preclinical development as product candidates to treat hematologic malignancies and solid tumors, as well as infectious diseases. For more information about the company, please visit www.arnothera.com .

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. These statements are often, but not always, made through the use of words or phrases such as "anticipates," "expects," "plans," "believes," "intends," and similar words or phrases. These forward-looking statements include, without limitation, statements regarding the timing, progress and anticipated results of the clinical development of onapristone, including the ability to identify and treat those patients most likely to benefit from onapristone, as well as Arno's strategy, future operations, outlook, milestones, future financial position, future financial results, plans and objectives. Arno may not actually achieve these plans, intentions or expectations and Arno cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements made here. Various important factors could cause actual results or events to differ materially from these forward-looking statements. Such factors include, among others, risks that the results of clinical trials will not support claims or beliefs concerning the effectiveness of onapristone or any other product candidates, the ability to successfully develop a diagnostic to identify APR tumors, the ability to finance the development of Arno's product candidates, regulatory risks, and reliance on third party researchers and other collaborators. Additional risks are described in the company's Annual Report on Form 10-K for the year ended December 31, 2014. Arno is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

The Ruth Group Lee Roth (investors) (646) 536-7012 Kirsten Thomas (media) (646) 536-7014 Arno Therapeutics Lawrence Kenyon (862) 703-7171

Scroll down for more posts ▼

Top 10 Most Recent News Articles

YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 124

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 7

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 415

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 324

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 136

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 77

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 42

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 44

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 416

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 258

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation into Inspire Medical Systems: What Investors Need to Know

Updated Category News Views 166

Investigation of Inspire Medical Systems and Shareholder Rights Faruqi & Faruqi, LLP, a prominent player in the field of securities law, is taking proactive steps to investigate potential claims regarding Inspire Medical Systems, Inc. This company has garnered attention recently due to its significant developments and ongoing operations. Investors who have experienced...

Continue Reading
Ecopro BM Faces Downgrade Amidst Battery Industry Challenges

Updated Category News Views 71

Market Response to Ecopro BM's Stock Downgrade Recently, Ecopro BM Co Ltd (247540:KS) faced a significant shift in its market perception as Nomura/Instinet downgraded the company's stock rating from Buy to Neutral. This adjustment comes with a newly revised price target focused on KRW240,000, a notable decrease from the previous KRW290,000. The decision is primarily...

Continue Reading
Exploring the Current State of Sea's Options Trading Landscape

Updated Category News Views 163

Exploring the Current State of Sea's Options Trading Landscape Recent market movements surrounding Sea (NYSE: SE) have sparked considerable interest among investors and traders alike. A comprehensive analysis of the options trading history for Sea reveals notable bearish activity. In our investigation, we identified 16 unusual trades that reflect a cautious outlook among...

Continue Reading
Empowering Women in Whiskey: The Rise of Lythgoe Bourbon

Updated Category News Views 94

Celebrating Women in the Whiskey Industry with Lythgoe Bourbon In a male-dominated field, one entrepreneur is making waves by honoring women in whiskey. The story of Lythgoe Bourbon begins with Dina Coker, who recognized a remarkable trend in the bourbon market. Despite the traditional narrative focused on male brands and locations in Kentucky, women are a significant...

Continue Reading
Waste Connections Declares Quarterly Cash Dividend for Investors

Updated Category News Views 110

Waste Connections Announces Regular Quarterly Cash Dividend Waste Connections, Inc. (TSX/NYSE: WCN) is making strides in providing returns for its shareholders by declaring a regular quarterly cash dividend of $0.315 U.S. per common share. This decision was made by the Company's Board of Directors and reflects their commitment to offering consistent shareholder value. The...

Continue Reading